Nisa Investment Advisors LLC Has $1.40 Million Position in Baxter International Inc. $BAX

Nisa Investment Advisors LLC cut its stake in Baxter International Inc. (NYSE:BAX) by 33.7% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 60,830 shares of the medical instruments supplier’s stock after selling 30,904 shares during the quarter. Nisa Investment Advisors LLC’s holdings in Baxter International were worth $1,397,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of BAX. MassMutual Private Wealth & Trust FSB increased its stake in Baxter International by 40.1% in the second quarter. MassMutual Private Wealth & Trust FSB now owns 2,831 shares of the medical instruments supplier’s stock valued at $86,000 after purchasing an additional 810 shares in the last quarter. Fiduciary Alliance LLC bought a new position in shares of Baxter International during the second quarter worth $1,914,000. Farther Finance Advisors LLC grew its holdings in shares of Baxter International by 24.6% in the 2nd quarter. Farther Finance Advisors LLC now owns 9,326 shares of the medical instruments supplier’s stock valued at $282,000 after buying an additional 1,839 shares during the period. Farmers & Merchants Investments Inc. increased its position in shares of Baxter International by 34.9% in the 2nd quarter. Farmers & Merchants Investments Inc. now owns 21,255 shares of the medical instruments supplier’s stock valued at $644,000 after buying an additional 5,500 shares in the last quarter. Finally, Public Employees Retirement System of Ohio increased its position in shares of Baxter International by 1.4% in the 2nd quarter. Public Employees Retirement System of Ohio now owns 159,040 shares of the medical instruments supplier’s stock valued at $4,816,000 after buying an additional 2,226 shares in the last quarter. Institutional investors own 90.19% of the company’s stock.

Baxter International Stock Up 1.0%

BAX stock opened at $19.85 on Thursday. The company has a debt-to-equity ratio of 1.21, a current ratio of 1.84 and a quick ratio of 1.18. The stock has a market capitalization of $10.20 billion, a P/E ratio of -30.07, a P/E/G ratio of 1.15 and a beta of 0.59. Baxter International Inc. has a fifty-two week low of $17.40 and a fifty-two week high of $37.74. The business has a 50-day moving average of $18.94 and a 200-day moving average of $22.58.

Baxter International (NYSE:BAX) last announced its earnings results on Thursday, October 30th. The medical instruments supplier reported $0.69 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.60 by $0.09. Baxter International had a positive return on equity of 17.38% and a negative net margin of 3.09%.The business had revenue of $2.84 billion for the quarter, compared to analyst estimates of $2.88 billion. During the same quarter last year, the firm earned $0.80 EPS. Baxter International’s revenue for the quarter was up 5.0% compared to the same quarter last year. Baxter International has set its Q4 2025 guidance at 0.520-0.570 EPS and its FY 2025 guidance at 2.350-2.400 EPS. On average, sell-side analysts anticipate that Baxter International Inc. will post 2.48 earnings per share for the current fiscal year.

Baxter International Cuts Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, January 2nd. Investors of record on Friday, November 28th were issued a dividend of $0.01 per share. The ex-dividend date was Friday, November 28th. This represents a $0.04 annualized dividend and a yield of 0.2%. Baxter International’s dividend payout ratio is presently -6.06%.

Analyst Ratings Changes

Several research analysts have weighed in on the company. Stifel Nicolaus reduced their target price on Baxter International from $25.00 to $22.00 in a report on Friday, October 31st. Cowen reaffirmed a “hold” rating on shares of Baxter International in a research report on Thursday, October 30th. UBS Group cut their price objective on Baxter International from $24.00 to $21.00 and set a “neutral” rating on the stock in a report on Friday, October 31st. Barclays decreased their price objective on Baxter International from $36.00 to $30.00 and set an “overweight” rating for the company in a research report on Friday, January 9th. Finally, Morgan Stanley dropped their target price on shares of Baxter International from $19.00 to $15.00 and set an “underweight” rating on the stock in a report on Tuesday, December 2nd. Two investment analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $21.30.

Baxter International Company Profile

Baxter International Inc is a global healthcare company that develops, manufactures and markets a broad portfolio of medical products, pharmaceutical therapies and biotechnology-based solutions. The company’s primary business activities are organized around renal care, medication delivery, acute therapies, pharmacy automation, surgical care and biotechnology. Baxter’s offerings are designed to support patient care in hospitals, dialysis centers, nursing homes and other healthcare facilities worldwide.

In the renal care segment, Baxter provides hemodialysis and peritoneal dialysis systems, water treatment equipment and related disposables, including dialyzers, bloodlines and catheters.